Sustained Ocular and Neural Drug Delivery With Multi-Agent Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inherited or age-related choroid, retina, optic nerve disorders, otic disorders, neurologic disorders, and CNS disorders, as well as conditions related to blood vessel occlusion or obstruction, such as stroke and myocardial or renal infarction, are inadequate in providing sustained therapeutic levels of neurotrophic agents, apoptosis signaling fragment inhibitors, TNF-α inhibitors, mitochondrial peptides, chemokine inhibitors, or cysteine-aspartic protease inhibitors.
Innovation Solution
A drug delivery system comprising a neurotrophic agent, FAS/FASL inhibitor, TNF-α/TNFR inhibitor, mitochondrial peptide, oligonucleotide, chemokine inhibitor, or cysteine-aspartic protease inhibitor, optionally with a sustained delivery component, to provide therapeutic levels of these compounds for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current treatments are used for neurotrophic agents, apoptosis signaling fragment inhibitors, TNF-α inhibitors, mitochondrial peptides, chemokine inhibitors, or cysteine-aspartic protease inhibitors, then the treatment can be administered, but the therapeutic levels are not sustained for adequate durations
Solution Approach 1:
The treatment regimen is segmented into multiple dosing administrations spaced at intervals, where each dose replenishes the therapeutic agent levels that have declined from the previous dose. This segmentation of continuous therapy into discrete dosing events allows the drug to be administered at manageable intervals while maintaining sustained therapeutic coverage over time.
Solution Approach 2:
The treatment employs periodic administration of therapeutic agents at predetermined intervals (e.g., weekly, bi-weekly, monthly). This periodic dosing strategy creates oscillating but sustained therapeutic levels, where each periodic dose restores levels that naturally decline over time, ensuring consistent therapeutic effect without requiring continuous infusion.
2Reliability
If multiple therapeutic agents are combined in a drug delivery system, then the treatment efficacy is improved, but the device complexity increases
Solution Approach 1:
Multiple therapeutic agents (neurotrophic agents, apoptosis signaling fragment inhibitors, TNF-α inhibitors, mitochondrial peptides, chemokine inhibitors, or cysteine-aspartic protease inhibitors) are merged into a single integrated drug delivery system. This combination approach allows concurrent administration of multiple agents that target different pathways in neurodegenerative diseases, improving overall treatment efficacy while simplifying the patient regimen by consolidating multiple treatments into one system.
Solution Approach 2:
The drug delivery system is designed with multi-functionality to accommodate various types of therapeutic agents simultaneously. The system can deliver neurotrophic agents, apoptosis inhibitors, TNF-α inhibitors, mitochondrial peptides, chemokine inhibitors, and caspase inhibitors through a unified delivery mechanism, making it universally applicable to different disease mechanisms and stages.
Data Source
AI summary
This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease (caspase) inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.